Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur A Levin

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Antisense & Nucleic Acid Drug Development|April 15, 2003
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimensRosie Z Yu, John Q Su, John S Grundy, et al.
Nucleic Acid Therapeutics|August 6, 2014
Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serumScott P Henry, Mark A Jagels, Tony E Hugli, et al.
Science (New York, N.Y.)|March 1, 2003
More on science and politicsGary D Bass, Paul D Blumenthal, Phil Corfman, et al.
Nucleic Acid Therapeutics|August 24, 2012
The Oligonucleotide Safety Working Group (OSWG)Dave Schubert, Arthur A Levin, Doug Kornbrust, et al.
International Immunopharmacology|December 10, 2002
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotideScott P Henry, Greg Beattie, Grace Yeh, et al.
Journal of Pharmaceutical Sciences|May 5, 2004
Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprateAraz A Raoof, Peter Chiu, Zeibun Ramtoola, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across speciesRichard S Geary, Rosie Z Yu, Tanya Watanabe, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 9, 2013
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9Eveline P van Poelgeest, Reinout M Swart, Michiel G H Betjes, et al.
Biochemical Pharmacology|December 6, 2008
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100Rosie Z Yu, Kristina M Lemonidis, Mark J Graham, et al.
British Journal of Clinical Pharmacology|August 12, 2015
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trialEveline P van Poelgeest, Michael R Hodges, Matthijs Moerland, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Antisense & Nucleic Acid Drug Development|April 15, 2003
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimensRosie Z Yu, John Q Su, John S Grundy, et al.
Nucleic Acid Therapeutics|August 6, 2014
Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serumScott P Henry, Mark A Jagels, Tony E Hugli, et al.
Science (New York, N.Y.)|March 1, 2003
More on science and politicsGary D Bass, Paul D Blumenthal, Phil Corfman, et al.
Nucleic Acid Therapeutics|August 24, 2012
The Oligonucleotide Safety Working Group (OSWG)Dave Schubert, Arthur A Levin, Doug Kornbrust, et al.
International Immunopharmacology|December 10, 2002
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotideScott P Henry, Greg Beattie, Grace Yeh, et al.
Journal of Pharmaceutical Sciences|May 5, 2004
Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprateAraz A Raoof, Peter Chiu, Zeibun Ramtoola, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across speciesRichard S Geary, Rosie Z Yu, Tanya Watanabe, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 9, 2013
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9Eveline P van Poelgeest, Reinout M Swart, Michiel G H Betjes, et al.
Biochemical Pharmacology|December 6, 2008
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100Rosie Z Yu, Kristina M Lemonidis, Mark J Graham, et al.
British Journal of Clinical Pharmacology|August 12, 2015
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trialEveline P van Poelgeest, Michael R Hodges, Matthijs Moerland, et al.
Pageof 4